CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
OPERATING ACTIVITIES:
Net income (loss)	$ (33,366)	$ (272,107)	$ 28,690
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	56,309	55,594	55,115
Deferred income tax expense (benefit)	(8,585)	(87,242)	30,690
Share-based compensation	10,216	9,027	9,896
Asset impairment charges	34,448	375,381	24,960
Loss (gain) on sale/disposal of assets	(159)	1,559	848
Gain on investment securities			(3,313)
Loss on extinguishment of debt	2,145	448
Loss on sale of intangible asset			15,514
Amortization of debt discount and other debt issuance costs	14,336	17,641	21,866
Other noncash (income) expenses	1,969	2,579	5
Changes in assets and liabilities which provided (used) cash:
Accounts receivable, net	39,064	84,949	(48,585)
Inventories	1,104	(2,336)	(19,031)
Prepaid income taxes/income taxes payable	(14,465)	18,319	2,174
Other assets	4,095	2,643	(2,287)
Rebates payable	(8,000)	(3,225)	4,807
Royalties payable	4,648	10,260	2,940
Restructuring liability	(2,288)	(4,391)	1,275
Operating lease liability	(1,464)
Accounts payable	19,042	(43,274)	(4,953)
Accrued expenses	2,213	(1,620)	(5,074)
Accrued payroll and payroll-related expenses	(3,620)	12,105	2,986
Other liabilities	(1,628)
Net cash provided by operating activities	116,014	176,310	118,523
INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(18,330)	(24,340)	(52,316)
Proceeds from sale of property, plant and equipment	7,380	14,450	28
Proceeds from sale of outstanding loan to Variable Interest Entity ("VIE")		5,600
Advance to VIE	250		10,254
Purchases of intangible assets	(28,800)	(3,000)	(19,038)
Proceeds from sale of investment securities			94,047
Purchase of investment securities			(63,643)
Net cash used in investing activities	(40,000)	(7,290)	(51,176)
FINANCING ACTIVITIES:
Proceeds from issuance of long-term debt	86,250
Purchase of capped call	(7,072)
Repayments of short-term borrowings and long-term debt	(146,700)	(126,743)	(85,705)
Proceeds from issuance of stock	998	1,180	4,142
Payment of debt issuance costs	(3,489)	(1,102)
Purchase of treasury stock	(1,909)	(592)	(4,642)
Net cash used in financing activities	(71,922)	(127,257)	(86,205)
Effect on cash and cash equivalents of changes in foreign exchange rates	(12)	(100)	(293)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	4,080	41,663	(19,151)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	140,249	98,586	117,737
CASH AND CASH EQUIVALENTS, END OF PERIOD	144,329	140,249	98,586
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid (net of amounts capitalized of $0, $0 and $1.6 million for the years ended June 30, 2020, 2019 and 2018, respectively)	51,928	66,750	63,563
Income taxes paid (refunded)	7,787	(4,641)	(6,559)
Accrued purchases of property, plant and equipment	$ 2,295	765	3,572
Credits issued pursuant to a Settlement Agreement			$ 17,000
Andor Pharmaceuticals, LLC ("Andor") License Agreement acquisition		$ 16,000